OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
28
Results
Show all
Save search
Copy query
Show results for
Unknown
(28)
Publication Date
Release Date
2023
(8)
2022
(5)
2025
(4)
2011
(4)
2021
(2)
2024
(1)
2016
(1)
2015
(1)
2013
(1)
2012
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.
Not available
S-EPMC10686688
|
biostudies-literature
Cite
Variant-Specific Viral Kinetics in Acute COVID-19.
Not available
S-EPMC10469346
|
biostudies-literature
Cite
Immune Status and SARS-CoV-2 Viral Dynamics.
Not available
S-EPMC10469582
|
biostudies-literature
Cite
Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19.
Not available
S-EPMC10469105
|
biostudies-literature
Cite
Long COVID After Bamlanivimab Treatment.
Not available
S-EPMC10686694
|
biostudies-literature
Cite
Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19.
Not available
S-EPMC9709705
|
biostudies-literature
Cite
Results of the two incidence screenings in the National Lung Screening Trial.
Not available
S-EPMC4307922
|
biostudies-literature
Cite
A multicenter study to map genes for Fuchs endothelial corneal dystrophy: baseline characteristics and heritability.
Not available
S-EPMC3719980
|
biostudies-literature
Cite
The National Lung Screening Trial: overview and study design.
Not available
S-EPMC3009383
|
biostudies-literature
Cite
Acetaminophen versus Ibuprofen in Young Children with Mild Persistent Asthma.
Not available
S-EPMC5085065
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets